Solid Tumor Therapeutics Market
Report ID: SQMIG35H2369
Report ID: SQMIG35H2369
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2369 |
Region:
Global |
Published Date: December, 2025
Pages:
187
|Tables:
95
|Figures:
71
Global Solid Tumor Therapeutics Market size was valued at USD 191.58 Billion in 2024 and is poised to grow from USD 207.29 Billion in 2025 to USD 389.4 Billion by 2033, growing at a CAGR of 8.2% in the forecast period (2026–2033).
Increasing cases of many cancers including breast cancer, lung cancer, colorectal cancer, and prostate cancer, are driving growth of the growth solid tumor therapeutics market. As the population ages, and as new lifestyles are created with increased risk factors including smoking, unhealthy foods, and decrease in activity levels, cases of solid tumors are expected to rise. All of this creates a need for an effective solid tumor therapeutic option. In addition to the disease's effects on patients, many advanced therapeutic options that include targeted therapies, immunotherapies, and combinations have been adopted to increase patient outcomes, as opposed to traditional chemotherapy. The surge of regulatory approvals for new solid tumor therapeutics and existing strong pipeline of oncology drugs is driving growth in the market. Pharmaceutical companies continue to spend millions of dollars towards R&D in order to develop personalized medicine solutions, now easier with the help of biomarkers and genomic profiling. Other contributing factors include higher healthcare expenditures, improved access to treatment in emerging economies, and favorable higher reimbursement rates in developed countries. The growing emphasis on value-based care also opens up new patient-driven transaction strategies that are allowing for increased penetration and adoption of new solid tumor therapies into healthcare at a global level.
How Is Artificial Intelligence (AI) Revolutionizing Precision and Personalization in the Solid Tumor Therapeutics Market?
Artificial Intelligence (AI) is disrupting the global solid tumor therapeutics market by enhancing precision of treatment personalization and redefining oncology workflows. In one way, AI enables clinicians and researchers to undertake real-time tumour profiling, automate treatment planning, and predict therapeutic response for individual patients, allowing for a faster, data-driven, and more precise intervention strategy. AI-derived analytics also permit the design of adaptive trials, determination of molecular targets, and early detection of resistance patterns, leading to swifter innovation in the oncology pipeline. At the same time, AI is broadening the therapeutic landscape, with the further creation of decision support systems integrating patient treatment decisions across radiomics, pathology, and genomics. These systems enable oncologists to provide more precise monitoring of tumor dynamics and to adjust immunotherapy or chemotherapy regimens by considering real world data.
For example, in May 2025 Roche entered a collaboration with PathAI to launch an AI-enabled platform that interprets images of digital pathology slides containing solid tumors used to help guide treatment selection in patients with non-small cell lung cancer. This platform enhances diagnostic certainty, promotes faster turnaround time, and will help play an important role in the expansion of personalized cancer care globally.
Market snapshot - 2026-2033
Global Market Size
USD 177.06 Billion
Largest Segment
Targeted Therapy
Fastest Growth
Immunotherapy
Growth Rate
8.20% CAGR
To get more insights on this market click here to Request a Free Sample Report
The global solid tumour therapeutics market is segmented based on therapy type, cancer indication, end user, and region. In terms of therapy type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. Based on cancer indication, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, and others. Based on end user, the market is segmented into hospitals, cancer research centers, and specialty clinics. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
According to the global solid tumor therapeutics market forecast, targeted therapy continues to dominate the market. Its competitive advantage is evident in its ability to preferentially target cancer cells by targeting specific molecular targets, thereby providing fewer side effects and better patient outcomes than traditional chemotherapy. Targeted therapy for solid tumors (i.e., breast, lung and colorectal cancer) has become the dominant choice due to its precision, efficacy and increasing number of marketed indications. Companion diagnostics and improvements in overall tumor profiling technologies called upon a leading role for targeted therapy in personalized cancer therapies.
Immunotherapy is expected to be the fastest-growing therapy type, with the biggest impact on cancer care and promise of long-lasting remissions as new frontiers for therapy. Immune checkpoint inhibitors and CAR-T cell therapies are showing unprecedented clinical success for certain solid tumors and are being granted expanded indications and accelerated regulatory pathways. Faster use of these therapies is being aided by the combination of immunotherapy alone or in complement with other modalities, as well as further public and private investments levied on immune-oncology therapies. Increased awareness from continued positive clinical outcomes and broadened access to immune-oncology therapies will speed up continued uptake.
Breast cancer is the leading cancer indication in the solid tumor therapeutics global market. Breast cancer takes the largest share of the market as its incidence is high on a global basis, screening programs are well established, and broad spectrum therapies are available including hormone therapy and targeted therapy, as well as immunotherapy. Treatment guidelines are standardized, public support is strong, and government and non-government programs for early detection and treatment could be considered strong in many countries.
Lung cancer is expected to be the fastest growing cancer indication over the next five years, because of the increasing incidence of non-small cell lung cancer (NSCLC) and the recent advances in immuno-oncology and targeted drugs aimed specifically to lung tumors. Furthermore, increasing early diagnosis rates, rising smoking cancer burden in emerging markets leading to increasing rates of smoking-related cancer, and an increased number of clinical trials underway related to novel agents will all contribute to lung cancer's growth. Lung cancer will continue to experience an increase in access to cutting-edge treatment options, as well as favorable reimbursement outcomes.
To get detailed segments analysis, Request a Free Sample Report
As per the global solid tumor therapeutics market analysis, North America dominates the global market owing to its advanced healthcare infrastructure, high prevalence of cancer, and substantial investments in oncology research. The region benefits from a well-established pharmaceutical sector, strong presence of key biopharmaceutical companies, and widespread availability of novel cancer therapies including targeted drugs and immunotherapies. Additionally, regulatory support from agencies like the U.S. Food and Drug Administration (FDA) has facilitated rapid approvals for breakthrough treatments, accelerating market growth. Increased public awareness, comprehensive insurance coverage, and access to clinical trials further strengthen North America's leadership in the global solid tumor therapeutics landscape.
The United States is the largest market in North America when it comes to solid tumor therapeutics, due to a high incidence of cancers including breast, lung, and colorectal cancer. The American market is capitalizing on the early embrace of precision medicine and numerous active oncology pipelines. There is an established clinical trial ecosystem, effective reimbursement policies, and increasing collaborations between research institutions and industry, all of which guarantee a future-changing solid tumor treatment with opportunities for market expansion.
The solid tumor therapeutics market in Canada is progressing positively with increases in cancer incidence, improved capabilities to diagnose, and the increase in healthcare spend. Canada is a model for improving access to oncology treatment with its national cancer strategies and careful use of provincial funding tools. The Canadian solid tumor therapeutics market is well positioned for future market growth as personalized medicine continues to evolve and healthcare systems continue to invest in integrated, patient-centered approaches to oncology.
Asia Pacific is the fastest-growing region in the solid tumor therapeutics market, driven by rising cancer burden, rapid improvements in healthcare infrastructure, and growing access to innovative treatments. Increasing healthcare insurance coverage, expanding clinical trial activities, and the presence of cost-effective manufacturing hubs are attracting global pharmaceutical companies to the region. With growing awareness, supportive regulatory reforms, and a rising middle-class population demanding better cancer care, Asia Pacific is poised for robust market expansion.
Japan is an important country for the general solid tumor therapeutics market in Asia Pacific, given its high incidence of cancer, aging population and good medical infrastructure. The country has embraced innovations in oncology therapeutics including both targeted therapies and immune checkpoint inhibitors as routine standard of care. As a result of the universal health care policy in Japan, solid tumor drugs can gain early market access thanks to expedited drug approvals, for these drugs to go through the Japanese regulatory decisions. Japan's position as a leader in clinical oncology and personalized medicine confirms its importance as part of the overall therapeutic landscape of the Asia Pacific region.
South Korea is experiencing robust growth in the solid tumor therapeutics market, with support from the New Health Technology Assessment (nHTA) processes, advancements in biotechnology, and increased government and public investments towards health care initiatives. The government's approach towards cancer detection, because of early screening programs and expansion of national health insurance coverage in South Korea, has taken a significant step toward improved access to treatment. Therefore, South Korea is promoting its position as an emerging leader in the Asia Pacific region oncology market.
Europe is strengthening its presence in the global solid tumor therapeutics market through stringent healthcare regulations, strong research funding, and robust national cancer control strategies. The region benefits from collaboration between academic institutions, research hospitals, and pharmaceutical companies, driving innovation in cancer therapeutics. With a rising elderly population and high healthcare spending, Europe remains a key region for solid tumor therapeutics development and commercialization.
Germany's solid tumor therapeutics market is the leading force in Europe, owing to its overall commitment to the best healthcare system in the world, a powerful pharmaceutical industry on the continent, and commitment to being a leader in clinical oncology research. Germany’s commitment to excellence in medicine and collaborative research with pharmaceutical and biotechnology companies continues to uphold its status in the European market.
The United Kingdom is firmly establishing itself as the fastest-growing solid tumor therapeutics market in Europe, driven primarily by the focus of the National Health Service (NHS) leadership on early detection of cancer. Coupled with an extraordinarily favorable clinical trial ecosystem and proactive policy environment resulting in fast-tracking new drug approvals, the UK has a very promising novel therapeutic landscape. All these components are allowing for significant growth of its solid tumor therapeutics market.
France is another established presence in the European solid tumor therapeutics market, supported by a national cancer strategy and proven health-care infrastructure. French pharmaceutical company research and development, together with leading French research institutions, are developing a multitude of new oncology treatments, including immunotherapies and molecularly targeted agents directed at novel cancer-specific targets.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advancements in Precision Oncology
Rising Cancer Incidence and Aging Population
High Treatment Costs and Access Barriers
Complex Regulatory Approval Processes
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global solid tumor therapeutics industry is shaped by continuous innovation, strategic partnerships, and therapeutic pipeline expansion. Leading pharmaceutical players such as Roche, Bristol Myers Squibb, Merck & Co., Novartis, and AstraZeneca dominate the market with robust oncology portfolios and global clinical trial networks. For example, Merck is building on its leadership position in immuno-oncology with expanded indications of Keytruda, while AstraZeneca is expanding its use of Tagrisso and Enhertu in targeted therapies. They are focusing on clinical relevance, regulatory approvals, and consistent leadership in oncology. The oncology market is also attracting a new generation of specialized biotech companies, many of which are oncology-focused, with new drug modalities and platforms for precision medicine. The application of artificial intelligence, biomarker discovery and adaptive trial designs is enabling these companies to quickly lead the way in bringing novel therapies for solid tumor indications. Their nimbleness allows for fast drug development timelines and flexibility to meet changing clinical needs. In this way, emerging biotech companies will pressure large pharmaceutical companies to be agile and nimble.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global solid tumor therapeutics market is rapidly advancing due to the rising cancer incidence, aging populations, and the integration of precision medicine and AI technologies. Growing uptake of targeted therapies, immunotherapies, and companion diagnostics is changing how care is delivered in the oncology patient group, while investment in biomarker-driven pharmaceutical research and development will continue to drive innovation across regional markets.
Regional opportunities are determined by healthcare infrastructure setting, price and access to treatment, as well as regulatory positioning. Understanding the barriers to adoption in some areas, such as high treatment costs, fragmented marketplace, and evolving treatment pathways, there are also many positives to discuss, such as the increasing physical presence of large biopharma, emerging biopharma, and different hospitals and treatment centers within assigned regions that create competition. Thus, innovation and growth are likely going to be very robust in the future.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 191.58 Billion |
| Market size value in 2033 | USD 389.4 Billion |
| Growth Rate | 8.2% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Solid Tumor Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Solid Tumor Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Solid Tumor Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Solid Tumor Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
